Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2007

Bayer Schering Taps VTT to Study Cancer Drug

  • VTT and Bayer Schering Pharma will collaborate to study the mode of action of a Bayer’s new cancer drug. As part of this two-year research contract, VTT will use its new gene and cell biology methods.

    VTT’s focus is on identifying primary driver genes and targets of genetic alterations in cancer. The company also works toward finding drug compounds preventing the growth and metastasis of breast and prostate cancer.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »